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Research Brief: No evidence that substance use causes ADHD symptoms in adolescence 
Abstract 
There is a robust association between ADHD symptoms and elevated substance use. Several 
plausible causal pathways from ADHD to substance use have been articulated and supported 
empirically. In this study, we tested the recent suggestion that substance use could also 
influences levels of ADHD symptoms. Using the three most recent waves of data from the 
Zurich Project on the Social Development of Children and Youth (z-proso) we found 
significant and strong cross-lagged effects of ADHD symptoms on substance use but no 
significant effects in the opposite direction. This suggests that individual differences in 
substance use are not related to increases in ADHD symptoms in adolescence. Adolescent 
onset symptoms of ADHD are thus unlikely to be caused by substance use and targeting 
substance use problems is unlikely to reduce ADHD symptoms.  
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Attention-deficit hyperactivity disorder is defined by impairing levels of 
hyperactivity/impulsivity and/or inattention (APA, 2013). There is a well-established 
association between ADHD symptoms and substance use (e.g. Lee et al., 2011) and various 
pathways have been identified by which ADHD symptoms can lead to increased substance 
use (e.g. Molina & Pelham, 2014). For example, ADHD symptoms with an onset in early 
childhood may transact with environmental risk factors leading to the emergence and 
escalation of behavioural problems over development, including substance use in adolescence 
and adulthood (e.g. Beauchaine & McNulty, 2013). Much less attention has been paid to the 
idea that substance use could create risk for later ADHD symptoms; however, with the 
increasing recognition that ADHD symptoms may not reach clinically significant levels until 
adolescence and beyond, a search for precipitating factors occurring beyond childhood has 
been initiated (e.g. see Castellanos, 2015). Substance use during adolescence may represent 
such a candidate (e.g. Crean et al., 2011; Squeglia et al., 2009). Substance use often first 
begins in adolescence where in many cultures it is considered a ‘rite of passage’ (e.g. Masten 
et al., 2009). However, Beauchaine & McNulty (2013) and others have noted that the relative 
immaturity of the prefrontal cortex during this period may make adolescents especially 
vulnerable to long term adverse effects of substance use (e.g. Casey & Jones, 2010). For 
example, substance use may be associated with disruptions to structure and function in the 
prefrontal and orbitofrontal regions associated with the behaviour regulation deficits 
characteristic of the hyperactive/impulsive and comorbid subtypes of ADHD (see Beauchaine 
& McNulty, 2013; Schoenbauma & Shamand, 2008). On this basis, a pathway from 
adolescent-onset substance use to later ADHD symptoms may be expected in addition to the 
widely-accepted ADHD-to-substance use pathway.   
Others have speculated about such a pathway. In one recent study, based on their 
results from a longitudinal study of smoking patterns, Brook et al. (2015) suggested that 
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‘smoking cessation in adolescence may lessen the likelihood of ADHD symptoms in 
adulthood’ (abstract; p.1). However, as ADHD with onset in late adolescence and adulthood 
has until recently received little attention and is not currently acknowledged within current 
diagnostic systems (e.g. APA, 2013) there is a paucity of longitudinal evidence on this 
potential relation. In this study we, therefore, aimed to test the hypothesis that there are bi-
directional links between ADHD symptoms and substance use (e.g. Beauchaine & McNulty, 
2013).  
 Method 
Ethics 
Given the minimally intrusive nature of the study design, questions and interventions, 
as well as the focus on social science research questions, the relevant Ethics Committee of the 
Canton of Zurich issued, based on the Swiss Human Research Act, a “declaration of no 
objection” for the z-proso project. It states that the project falls outside the remit of 
the Ethics Committee of the Canton of Zurich, and furthermore declared z-proso 
as ethically unproblematic. Informed consent from the participants were obtained in 
accordance with the relevant national regulations and all data were processed and stored 
according to data protection regulations.  
Participants and Measures 
 Data were from the most recent three waves of the Zurich project on the social 
development of children and youths (z-proso; http://www.cru.ethz.ch/en/projects/z-
proso.html). Z-proso is a normative sample longitudinal study of child and adolescent 
development that began in 2004 when the children entered school (aged 7). In the last three 
waves of data when the participants were aged 13, 15 and 17 respectively, n=1483 (51% 
male)provided data on their levels of substance use and ADHD symptomology.   
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 ADHD symptom levels were measured using the 4-item ADHD subscale of the Social 
Behavior Questionnaire (Tremblay et al., 1991). Previous analyses have supported the 
longitudinal invariance and reliability of this subscale (Murray et al., 2017). This comprises 
four items measuring inattention, hyperactivity and impulsivity. Responses were provided  on 
a 5-point Likert scale from never to very often.   
Substance use items were preceded by the instruction ‘Listed below are some drugs, 
intoxicants and other substances. Have you ever taken any of them and if yes, how many 
times in the last 12 months (i.e. since [DATE])?’. Participants then indicated tobacco, alcohol 
(beer/alcopops), alcohol (spirits) and cannabis use over the previous 12 months . Each was 
measured with a single item and responses provided on a 6-point scale from never to daily, 
specifically: (‘never’, ‘once’, ‘2 to 5 times’, ‘6 to 12-times (monthly)’, ’13 to 52 times 
(weekly)’ and ’53 to 365 times (daily)’. All measures were administered in German (the 
official language of the study location) in the context of a broader questionnaire measuring 
problem behaviour and related attitudes, experiences, risk factors and outcomes.  
Statistical procedure 
 Cross-lagged panel models with latent ADHD variables defined by the four SBQ 
items and substance use were fit separately for each substance. Latent variable scaling and 
identification were achieved by fixing the mean and variance of the ADHD factor at baseline 
to 1 and fixing the loading of the first item equal across time. Covariances between unique 
factors for corresponding items over time were freely estimated. Strict longitudinal invariance 
has previously been established for this measure in the current sample, therefore, metric 
invariance could be assumed (Murray et al., 2017). All first-order autoregressive and cross-
lagged effects and concurrent effects were included in the model. Concurrent effects i.e. 
(residual) covariances between substance use and ADHD symptoms within each time-point 
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were also included. Models were estimated in Mplus 7.13 using maximum likelihood 
estimation (Muthen & Muthen, 2014).  
Results 
  
 The cross-lagged models for all substances provided good fit to the data (tobacco: 
RMSEA=.04, CFI=.97, TLI=.96, SRMR=.03; alcohol (beer/alcopops): RMSEA=.05, 
CFI=.96, TLI=.94, SRMR=.04; alcohol (spirits): RMSEA=0.04, CFI=.97, TLI=.95, 
SRMR=.03; cannabis: RMSEA=.05, CFI=.96, TLI=.94, SRMR=.04). Cross-lagged and 
autoregressive parameters from the models are provided in Table 1-4. With the exception of 
the age 11 to 13 lag, ADHD had significant cross-lagged effects on all forms of substance use 
at all waves. There was, however, no evidence of any effect of substance use on ADHD 
across any lag.  
Discussion 
 There has been some recent speculation that substance use in adolescence could play 
a role in ADHD symptoms. High levels of substance use can adversely affect brain 
development and neuropsychological function during adolescence, thus, substance use may 
be a candidate causal factor in ADHD symptoms with onset in adolescence and adulthood.  
In this study, while we found evidence that individual differences in ADHD 
symptoms are related to future tobacco, alcohol and cannabis use controlling for past levels, 
there was no evidence that substance use affects ADHD symptom levels.  This suggests that 
substance use is not an important risk factor for increases in ADHD symptoms in normative 
populations. It is unlikely that substance use explains the symptom increases from childhood 
that occur in around 5% of individuals (e.g. Murray et al., 2016). There are several alternative 
explanations that may contribute to explaining ‘adolescent onset’ ADHD symptoms. One is 
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that individuals these carry the same underlying neurocognitive impairment as those with 
earlier onset symptoms but this does not manifest in detectable behaviours until social and 
academic demands become intensified and/or reliance on compensatory support within the 
school and family becomes less readily available (e.g. Caye et al., 2016). Alternatively, there 
may be a genuine change in underlying neurocognitive function in these individuals with 
concurrent changes in ADHD symptoms resulting from exposure to pathogenic factors. 
Finally, individuals with ‘adolescent onset’ symptoms may be expressing a qualitatively 
different underlying neurocognitive deficit than those with earlier onset symptoms. For 
example, Murray et al. (2016) hypothesised that those with an earlier onset symptoms are 
more likely to be expressing difficulties in ‘top down’ executive control processes while 
those with later onset symptoms are expressing difficulties relative to ‘bottom up’ executive 
control processes (e.g. Sonuga-Barke, 2003). Further longitudinal research tracking the 
course of ADHD symptoms and candidate risk factors over time will be required to 
disentangle these possibilities.  Finally, our results also imply that while reducing substance 
use is an important aim, such interventions would not be expected to prevent later increases 
in ADHD symptoms.  
Strengths and Limitations 
Our study used three waves of data in which both ADHD symptoms and substance 
use were measured, allowing us to implement a fully cross-lagged design. This allowed us to 
account for previous levels of ADHD when assessing effects of substance use. However, as 
our data was drawn from a large longitudinal study, the available measures of ADHD and 
substance use were brief and did not allow us to examine relations between subtypes of 
ADHD symptoms or substance use in detail. In addition, our measures of substance use 
captured frequency of use over a 12 month period but did not capture the extent of 
intoxication during each episode of substance use. Further, as our sample is drawn from the 
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general population rather than a high risk sample, the use of hard drugs was infrequent and 
we, therefore, could not evaluate their effects on ADHD symptoms. Finally, our results do 
not speak to onset of symptoms beyond age 17 and they do not rule out the possibility that the 
cumulative effects of chronically high levels of substance use could increase ADHD 
symptoms later in life. Future studies extending into young adulthood and beyond will be 
required to test this possibility.  
Conclusions  
 ADHD symptoms influence substance use across adolescence; however, contrary to 
recent speculation there is no evidence that the opposite is also true. Substance use is, 
therefore, unlikely to be an important cause of adolescent onset ADHD symptoms. 
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Table 1: 
Standardised auto-regressive and cross-lagged for tobacco and ADHD model 
Path β SE p 
ADHD13ADHD15 .606       .027      <.001 
ADHD15ADHD17 .646       .025      <.001 
tobacco13tobacco15 .490 .021 <.001 
tobacco15tobacco17 .664 .017 <.001 
ADHD13tobacco15 .103       .028       <.011 
ADHD15tobacco17 .045       .026       .086 
tobacco13ADHD15 -.014       .028      .611 
tobacco15ADHD17 -.022       .028      .421 
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Table 2: 
Standardised auto-regressive and cross-lagged for alcohol (beer/alcopops) and ADHD 
model 
Path β SE p 
ADHD13ADHD15 0.604       0.027      <.001 
ADHD15ADHD17 0.651       0.025      <.001 
alcohol(beer/alcopops)13alcohol(beer/alcopops)15 0.389 0.023 <.001 
alcohol(beer/alcopops)15alcohol(beer/alcopops)17 0.579 0.022 <.001 
ADHD13alcohol (beer/alcopops)15 0.154 0.029 <.001 
ADHD15alcohol (beer/alcopops)17 0.121 0.030 <.001 
alcohol(beer/alcopops)13ADHD15 0.011 0.028 0.682 
alcohol(beer/alcopops)15ADHD17 -0.043       0.028 0.127 
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Table 3: 
Standardised auto-regressive and cross-lagged for alcohol (spirits) and ADHD model 
Path β SE p 
ADHD13ADHD15 .609 .027 <.001 
ADHD15ADHD17 .641 .025 <.001 
alcohol(spirits)13alcohol(spirits)15 .327 .025 <.001 
alcohol(spirits)15alcohol(spirits)17 .503 .025 <.001 
ADHD13alcohol (spirits)15 .145 .030 <.001 
ADHD15alcohol (spirits)17 .145 .031 <.001 
alcohol(spirits)13ADHD15 -.024 .028 .219 
alcohol(spirits)15ADHD17 -.004 .028 .884 
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Table 3: 
Standardised auto-regressive and cross-lagged for alcohol (spirits) and ADHD model 
Path β SE p 
ADHD13ADHD15 .608 .027 <.001 
ADHD15ADHD17 .642 .025 <.001 
cannabis13cannabis15 -.016 .028 .561 
cannabis15cannabis17 -.008 .028 .784 
ADHD13cannabis15 .139 .030 <.001 
ADHD15cannabis17 .145 .027 <.001 
cannabis13ADHD15 -.016 .028 .561 
cannabis15ADHD17 -.008 .028 .784 
 
 
  
 
 
